Full Text of PDF (545k)
Article in Japanese
Abstract
Case Report
A case of advanced primary lung squamous cell carcinoma harboring EGFR mutation, treated very effectively by chemotherapy combined with an immune checkpoint inhibitor
Hidekazu Matsushima Hiroki Ohta Tomohiro Ohba Hideaki Yamakawa Keiichi Akasaka Masako Amano
Department of Respiratory Medicine, Saitama Red Cross Hospital
ABSTRACT
A 48-year-old male diagnosed with advanced primary lung squamous cell carcinoma harboring EGFR mutation with a high proportion of PD-L1 was assessed for progressive disease 5 months after administration of osimertinib. We treated him with second-line chemotherapy combined with an immune checkpoint inhibitor; multiple pulmonary metastases rapidly disappeared and the primary tumor decreased in size. We considered this case to be very effectively treated by chemotherapy in combination with an immune checkpoint inhibitor. Even in lung cancer cases harboring driver mutations, including EGFR, chemotherapy in combination with an immune checkpoint inhibitor should be considered, especially in cases with high proportions of PD-L1.
KEYWORDS
Lung cancer Squamous cell carcinoma EGFR mutation Immune checkpoint inhibitor (ICI)
Received 30 May 2020 ／ Accepted 1 Sep 2020
AJRS, 10(1): 45-49, 2021
Copyright © The Japanese Respiratory Society All Rights Reserved.